EP Patent

EP2256118A1 — Condensed imidazolo derivatives for the inhibition of aromatase

Assigned to Novartis Pharma GmbH Austria · Expires 2010-12-01 · 15y expired

What this patent protects

The present invention relates to novel imidazole derivatives that are used as aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aromatase.

USPTO Abstract

The present invention relates to novel imidazole derivatives that are used as aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aromatase.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: EP2256118A1
Jurisdiction: EP
Classification: —
Expires: 2010-12-01
Drug substance claim: No
Drug product claim: No
Assignee: Novartis Pharma GmbH Austria
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.